Breaking News Headlines Today | Ground News

See every side of every news story

pharmatimes.com image

News from pharmatimes.com

pharmatimes.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Is pharmatimes.com credible or reliable? Our Factuality score answers both of those questions. When it comes to pharmatimes.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about pharmatimes.com

Where is pharmatimes.com located?pharmatimes.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top pharmatimes.com News

Scotland first part of UK to approve ‘cutting edge’ treatment for stomach cancer

Scotland, United Kingdom · Scotland

Scotland first part of UK to approve ‘cutting edge’ treatment for stomach cancer

100% Left coverage: 1 sources

The Scottish Medicines Consortium has approved zolbetuximab – to be used together with chemotherapy – to treat those with advanced stomach cancer. Scotland has become the first part of the UK to approve a new treatment hailed as “cutting edge care” for patients with advanced stomach cancer. The Scottish Medicines Consortium (SMC) has given the go-ahead for the drug zolbetuximab to be used, together with chemotherapy. SMC vice-chair Dr Robert Pee…See the Story

ErVimmune Raises 17m Euros in Funding to Develop Cancer Vaccine

France · France

ErVimmune Raises 17m Euros in Funding to Develop Cancer Vaccine

The vaccine could be created as a ready-to-use product, rather than needing to be personalised See the Story

Nxera Reports Positive Outcomes for Daridorexant Phase III Insomnia Study

South Korea · South Korea

Nxera Reports Positive Outcomes for Daridorexant Phase III Insomnia Study

Nxera Pharma has announced positive top-line results from its Phase III study of daridorexant 50 mg, aimed at treating insomnia in adult and elderly patients in South Korea.The post Nxera reports positive outcomes for daridorexant Phase III insomnia study appeared first on Clinical Trials Arena.See the Story

Breaking News Topics Related to pharmatimes.com